diclofenac sodium solution
direct rx - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 16.05 mg in 1 ml - diclofenac sodium topical solution is indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s) (1). diclofenac sodium topical solution is contraindicated in the following patients: known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac sodium or any components of the drug product [see warnings and precautions (5.7, 5.9)]. history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8)]. in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions 8.1 pregnancy pregnancy category c prior to 30 weeks gestation; category d starting 30 weeks gestation. risk summary use of nsaids, including diclofenac, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsai
diclofenac sodium 1.5%- diclofenac sodium topical solution solution
sola pharmaceuticals - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 16.05 mg in 1 ml - diclofenac sodium topical solution is contraindicated in patients with a known hypersensitivity to diclofenac sodium or any other component of diclofenac sodium topical solution. diclofenac sodium topical solution is contraindicated in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.10)]. diclofenac sodium topical solution is contraindicated in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1)]. 8. use in specific populations 8.1 pregnancy pregnancy category c prior to 30 weeks gestation; category d starting 30 weeks gestation. teratogenic effects: there are no adequate and well-controlled studies of diclofenac sodium topical solution in pregnant women. diclofenac sodium topical solution should not be used by pregnant women as its safe use has not been adequately de
diclofenac sodium gel
lake erie medical dba quality care products llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 30 mg in 1 g - diclofenac sodium gel is indicated for the topical treatment of actinic keratoses (ak). sun avoidance is indicated during therapy. diclofenac sodium gel is contraindicated in patients with a known hypersensitivity to diclofenac, benzyl alcohol, polyethylene glycol monomethyl ether 350 and/or sodium hyaluronate. diclofenac sodium gel is contraindicated in the following patients: - in the setting of coronary artery bypass graft (cabg) surgery.
diclofenac sodium gel
glenmark pharmaceuticals inc., usa - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 30 mg in 1 g - diclofenac sodium gel is indicated for the topical treatment of actinic keratoses (ak). diclofenac sodium gel is contraindicated in the following patients: risk summary use of nsaids, including diclofenac sodium gel, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. because of these risks, limit dose and duration of diclofenac sodium gel use between about 20 and 30 weeks of gestation and avoid diclofenac sodium gel use at about 30 weeks of gestation and later in pregnancy. oligohydramnios/neonatal renal impairment use of nsaids at about 20 weeks gestation or later in pregnancy has been associated with cases of fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment. premature closure of fetal ductus arteriosus use of nsaids, including diclofenac sodium gel, at about 30 weeks gestation or later in pregnancy increases the risk of premature closure of the fetal d
diclofenac sodium and misoprostol tablet, delayed release
avkare - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1), misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - diclofenac sodium 50 mg - diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing nsaid-induced gastric and duodenal ulcers and their complications. for a list of factors that may increase the risk of nsaid-induced gastric and duodenal ulcers and their complications [see warnings and precautions (5.2) ]. diclofenac sodium and misoprostol is contraindicated in the following patients: ● known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac sodium/misoprostol, other prostaglandins, or any components of the drug product [see warnings and precautions ( 5.7 , 5.9 )] ● history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions ( 5.7 , 5.8 )] ● in the
diclofenac sodium- diclofenac sodium tablet, delayed release
lake erie medical dba quality care products llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets, usp and other treatment options before deciding to use diclofenac sodium delayed-release tablets, usp. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). diclofenac sodium delayed-release tablets are indicated: - for relief of the signs and symptoms of osteoarthritis - for relief of the signs and symptoms of rheumatoid arthritis - for acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis diclofenac sodium delayed-release tablets, usp are contraindicated in patients with known hypersensitivity to diclofenac. diclofenac sodium delayed-release should not be given to patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactoid reaction
diclofenac sodium- diclofenac sodium tablet, film coated, extended release
proficient rx lp - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - carefully consider the potential benefits and risks of diclofenac sodium extended-release tablets, usp and other treatment options before deciding to use diclofenac sodium extended-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). diclofenac sodium extended-release tablets are indicated: diclofenac sodium extended-release tablets, usp are contraindicated in patients with known hypersensitivity to diclofenac. diclofenac sodium extended-release tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactoid reactions , and precautions, general: preexisting asthma ). diclofenac sodium extended-release tablets are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg
diclofenac sodium and misoprostol tablet, delayed release
amneal pharmaceuticals llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1), misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - diclofenac sodium 50 mg - diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in adult patients at high risk of developing nsaid-induced gastric and duodenal ulcers and their complications. for a list of factors that may increase the risk of nsaid-induced gastric and duodenal ulcers and their complications [see warnings and precautions (5.3)] . diclofenac sodium and misoprostol delayed-release tablets are contraindicated in the following patients: - pregnancy. use of misoprostol, a component of diclofenac sodium and misoprostol delayed-release tablets, during pregnancy can result in maternal and fetal harm, including uterine rupture, abortion, premature birth, or birth defects [see warnings and precautions (5.1) and use in specific populations (8.1)] . - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.2)] . - active gastrointestinal bleeding [see warnings and precautions (5.3)] . - histo
diclofenac potassium tablet, film coated
redpharm drug, inc. - diclofenac potassium (unii: l4d5ua6cb4) (diclofenac - unii:144o8ql0l1) - diclofenac potassium 50 mg - carefully consider the potential benefits and risks of diclofenac potassium tablets and other treatment options before deciding to use diclofenac potassium tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings; gastrointestinal bleeding, ulceration, and perforation). diclofenac potassium tablets are indicated: • for treatment of primary dysmenorrhea • for relief of mild to moderate pain • for relief of the signs and symptoms of osteoarthritis • for relief of the signs and symptoms of rheumatoid arthritis diclofenac is contraindicated in the following patients: • known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see warnings; anaphylactic reactions, serious skin reactions). • history of asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylact
diclofenac sodium tablet, film coated, extended release
preferred pharmaceuticals inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 100 mg - carefully consider the potential benefits and risks of diclofenac sodium extended-release tablets and other treatment options before deciding to use diclofenac sodium extended-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings; gastrointestinal bleeding, ulceration, and perforation ). diclofenac sodium extended-release tablets are indicated: diclofenac sodium extended-release tablets are contraindicated in the following patients: